Note: The full article and accompanying features are only available whilst being signed in.
Summary
A lot of attention is currently on the larger emerging markets that have significantly more growth than the mature markets. These are seen as a pick-me-up to some of the ailments of the global industry. Japan is the second largest drug market after the USA, and is considered a mature market in many respects. Like many mature markets it is not seeing the double-digit growth of many of the emerging markets.
Want more?
The content of this page been summarized. To view the full content, please register or sign in to the Eularis web site.
Register with Eularis
or
Sign in